
NCCN Adds Taletrectinib to ROS1+ NSCLC Recommendations
The National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend taletrectinib (Ibtrozi) as the preferred treatment for patients with ROS1-positive non–small cell lung cancer (NSCLC) as of June 20, according to a press release from …